AXS-14 (esreboxetine) is a novel, oral, investigational medicine. It is a highly selective and potent norepinephrine reuptake inhibitor.
Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine.
AXS-14 has met the primary endpoints and demonstrated positive and statistically significant results in a Phase 3 and in a Phase 2 trial for the treatment of fibromyalgia.
AXS-14 is an investigational drug not approved by the FDA and its safety and effectiveness have not been established.
AXS-14 is currently being developed for the treatment of fibromyalgia. The product is in the preparing to submit an NDA phase of development.
You will now be sent to a website that is not controlled or owned by Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. is not responsible or liable for the website you are about to go to, which may not be appropriate for everyone.